INVESTIGATING NEURON-SPECIFIC ENOLASE AS A DIAGNOSTIC MARKER FOR EARLY DETECTION OF DIABETIC PERIPHERAL NEUROPATHY IN PATIENTS WITH TYPE II DIABETES MELLITUS
Main Article Content
Keywords
Neuron specific Enolase, Diabetic peripheral neuropathy, enzyme-linked immunosorbent assay, diabetic foot, limb amputations
Abstract
Diabetic peripheral neuropathy is one of the serious complications of diabetes, often goes undetected until the advanced stages, resulting in serious health consequences such as loss of sensation, diabetic foot, limb amputations, kidney damage, and eyesight losses.
A total of 148 Type II diabetes mellitus patients were included in the study.Patients were equally divided into, two groups based on MSNI (Michigan Neuropathy Screening Instrument) 74 cases with positive symptoms of peripheral diabetic neuropathy and 74 control diabetic patients without symptoms of peripheral diabetic neuropathy. Vital signs and basic lab parameters were determined for all the studied groups.
The neuron-specific enolase (NSE) levels was measured by the Enzyme-linked immunosorbent assay (ELISA) method. The results of our study revealed that levels of NSE were elevated with high HbA1C, abnormal lipid profile among the patients with diabetic peripheral neuropathy symptom as compared to control group (0.69 ± 0.31 vs 0.48 ± 0.28; p-value <0.001) odds of diabetic complication were increased with the raise in HbA1C aOR 50.25, 95% CI 6.82-369.86. Similarly, odds of having diabetic complications increased with the raise in LDL and triglyceride aOR 1.03, 95% CI 1.00-1.07 and aOR 1.01, 95% CI 1.00-1.03. NSE level were found significant in univariate analysis which shows the odds of having diabetic complication increased with the increase in NSE level COR 9.79, 95% CI 3.08 – 31.16. Results of our study suggested that NSE may serve as a biomarker for the early detection of diabetic peripheral neuropathy.
References
Gase and S. Auciello, "66. TYPE 2 DIABETES MELLITUS," in The Resident's Guide to Ambulatory Care, Ed. 8.1: Frequently Encountered and Commonly Confused Clinical Conditions, 2024, p. 289.
2. S. Alam, et al., "Diabetes Mellitus: insights from epidemiology, biochemistry, risk factors, diagnosis, complications and comprehensive management," World Journal of Diabetes Research, vol. 2, no. 2, pp. 36-50, 2021.
3. M. J. A. Adinortey, "Biochemicophysiological mechanisms underlying signs and symptoms associated with diabetes mellitus," Advances in Biochemistry Research, vol. 11, no. 6, pp. 382-390, 2017.
4. P. Garg and N. J. O. M. Duggal, "Type 2 diabetes mellitus, its impact on quality of life and how the disease can be managed-a review," Open Medicine, vol. 35, p. 100459, 2022.
5. S. M. Genuth, J. P. Palmer, and D. M. Nathan, "Classification and diagnosis of diabetes," 2021.
6. P. A. Cortesi, et al., "Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis," Acta Diabetologica, pp. 1-12, 2024.
7. J. Reed, S. Bain, and V. Kanamarlapudi, "A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives," Diabetes Metab. Syndr. Obes., vol. 14, pp. 3567-3602, 2021.
8. M. K. Sahu and S. P. Tiwari, "Epidemiology, Pathogenesis and Treatment of Diabetes: A Comprehensive Review," World Journal of Diabetes Research and Practice, vol. 1, no. 1, pp. 01-09, 2024.
9. L. Bitterfeld and S. M. Reed, "Conceptualizing Treatment Burden among People with Type 2 Diabetes," Nursing Forum, 2024, Wiley Online Library.
10. J. J. Jóźwiak, "Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021," The Lancet, vol. 402, no. 10397, 2023.
11. H. Sun, et al., "IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045," Diabetes Res. Clin. Pract., vol. 183, p. 109119, 2022.
12. M. B. Shahid, et al., "Diabetes mellitus: Is Pakistan the epicenter of the next pandemic?" Diabetes Res. Clin. Pract., vol. 10, no. 01, pp. 75-77, 2024.
S. Shera, F. Jawad, and A. Maqsood, "Prevalence of diabetes in Pakistan," Diabetes Res. Clin. Pract., vol. 76, no. 2, pp. 219-222, 2007.
13. S. Azeem, U. Khan, and A. Liaquat, "The increasing rate of diabetes in Pakistan: A silent killer," Ann. Med. Surg. (Lond), vol. 79, p. 103901, 2022.
14. R. Pop-Busui, et al., "Diagnosis and treatment of painful diabetic peripheral neuropathy," 2022.
15. J. Zhu, et al., "Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment," Front. Endocrinol., vol. 14, p. 1265372, 2024.
16. S. Tesfaye and D. Selvarajah, "Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy," Diabetes Metab. Res. Rev., vol. 28, Suppl. 1, pp. 8-14, 2012.
17. International Diabetes Federation (IDF), Diabetes Atlas, 2019.
18. J. Carmichael, et al., "Advances in Screening, Early Diagnosis and Accurate Staging of Diabetic Neuropathy," Front. Endocrinol. (Lausanne), vol. 12, p. 671257, 2021.
19. J. D. England, et al., "Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation," Neurology, vol. 64, no. 2, pp. 199-207, 2005.
20. G. J. Bönhof, et al., "Emerging biomarkers, tools, and treatments for diabetic polyneuropathy," 2019, vol. 40, no. 1, pp. 153-192.
Haque, et al., "New insights into the role of neuron-specific enolase in neuro-inflammation, neurodegeneration, and neuroprotection," 2018, vol. 8, no. 2, pp. 33.
21. S. A. Vinores and L. J. Rubinstein, "Simultaneous expression of glial fibrillary acidic (GFA) protein and neuron-specific enolase (NSE) by the same reactive or neoplastic astrocytes," Neuropathol. Appl. Neurobiol., vol. 11, no. 5, pp. 349-359, 1985.
22. F. Liu, et al., "Research progress of neuron-specific enolase in cognitive disorder: a mini review," Front. Hum. Neurosci., vol. 18, p. 1392519, 2024.
23. F. Majeed, et al., "Potential predictive biomarker for diabetic peripheral neuropathy: serum neuron-specific enolase," 2023.
24. R. E. Eworo, et al., "Assessment of neuron-specific enolase, glycated haemoglobin and fasting plasma glucose levels in patients with diabetes peripheral neuropathy in Calabar Metropolis, Nigeria: A case control study," 2022, vol. 15, p. 17.
25. Z. J. Ghaib, et al., "Assessment of Neuron Specific Enolase Level and some Related Biochemical Factors in Patients with Diabetic Peripheral Nerve Disorders," 2021, vol. 15, no. 3.
26. H. R. Fateh, et al., "Correlation of Michigan neuropathy screening instrument, United Kingdom screening test and electrodiagnosis for early detection of diabetic peripheral neuropathy," 2015, vol. 15, pp. 1-5.
27. M. Lunetta, et al., "A simplified diagnostic test for ambulatory screening of peripheral diabetic neuropathy," 1998, vol. 39, no. 3, pp. 165-172.
28. J. Li, et al., "NSE, a potential biomarker, is closely connected to diabetic peripheral neuropathy," 2013, vol. 36, no. 11, pp. 3405-3410.
S. Babkina, et al., "Neuron-Specific Enolase—What Are We Measuring?" 2024, vol. 25, no. 9, p. 5040.
29. Q. Xiong, et al., "The diagnostic value of neuropathy symptom and change score, neuropathy impairment score and Michigan neuropathy screening instrument for diabetic peripheral neuropathy," 2016, vol. 74, no. 5-6, pp. 323-327.
30. N. Strand, et al., "Diabetic Neuropathy: Pathophysiology Review," Curr. Pain Headache Rep., vol. 28, no. 6, pp. 481-487, 2024.
Kulkarni, A. R. Thool, and S. Daigavane, "Understanding the Clinical Relationship Between Diabetic Retinopathy, Nephropathy, and Neuropathy: A Comprehensive Review," Cureus, vol. 16, no. 3, 2024.
31. W. Perveen, et al., "Prevalence of peripheral neuropathy, amputation, and quality of life in patients with diabetes mellitus," Sci. Rep., vol. 14, no. 1, p. 14430, 2024.
32. T. Oshitari, "Advanced glycation end-products and diabetic neuropathy of the retina," Int. J. Mol. Sci., vol. 24, no. 3, p. 2927, 2023.
33. Y. Çetinkaya, et al., "Presence of subclinical polyneuropathy in patients with elevation of Hba1c," Arch. Neuropsychiatry, vol. 61, no. 1, p. 55, 2024.
E. Butler, S. C. Hunt, and E. S. Kilpatrick, "Using nephropathy as an outcome to determine the HbA1c diagnostic threshold for type 2 diabetes," Diabetes Metab. Syndr. Clin. Res. Rev., vol. 18, no. 4, p. 103005, 2024.
34. M. D. Firouzabadi, et al., "Glycemic profile variability: An independent risk factor for diabetic neuropathy in patients with type 2 diabetes," Prim. Care Diabetes, vol. 17, no. 1, pp. 38-42, 2023.
35. K. Nozawa, M. Ikeda, and S. J. D.-R. W. O. Kikuchi, "Association Between HbA1c Levels and Diabetic Peripheral Neuropathy: A Case–Control Study of Patients with Type 2 Diabetes Using Claims Data," Diabetes Res. Open, vol. 9, no. 3, pp. 403-414, 2022.
36. K.-C. Chang, et al., "The association between hyperlipidemia, lipid-lowering drugs and diabetic peripheral neuropathy in patients with type 2 diabetes mellitus," 2023, vol. 18, no. 6, p. e0287373.
37. Z. Cai, Y. Yang, and J. Zhang, "A systematic review and meta-analysis of the serum lipid profile in prediction of diabetic neuropathy," Sci. Rep., vol. 11, no. 1, p. 499, 2021.
38. J. M. E. Jende, et al., "Association of Serum Cholesterol Levels With Peripheral Nerve Damage in Patients With Type 2 Diabetes," JAMA Netw Open, vol. 2, no. 5, p. e194798, 2019.
39. R. Amelia, et al., "Early Detection of Diabetic Peripheral Neuropathy in Diabetic Patients: A Cross-Sectional Study," Curr. Diabetes Rev., 2024.
C. Razavi, et al., "Does elevated high-density lipoprotein cholesterol protect against cardiovascular disease?," J. Clin. Endocrinol. Metab., vol. 109, no. 2, pp. 321-332, 2024.
40. D. Tsilingiris, et al., "Dysmetabolism-related early sensory deficits and their relationship with peripheral neuropathy development," J. Clin. Endocrinol. Metab., vol. 108, no. 10, pp. e979-e988, 2023.
41. S. E. Ahmed, E. Mustafa, and E. M. J. AbdulRaheem, "Assessment of plasma levels of fasting blood glucose, triglycerides, total cholesterol, and HbA1c in patients with type 2 diabetes mellitus," Diabetes Res., vol. 13, p. 16, 2013.
42. M. M. Yassin, H. I. Altibi, and A. F. Elshanti, "Clinical and biochemical features of type 2 diabetic patients in Gaza Governorate, Gaza Strip," West Afr. J. Med., vol. 30, no. 1, pp. 51-56, 2011.
43. T. Chen, et al., "Risk factors for peripheral artery disease and diabetic peripheral neuropathy among patients with type 2 diabetes," Diabetes Res. Clin. Pract., vol. 207, p. 111079, 2024.
44. J. A. Ismoilov, et al., "Dysfunctional high-density lipoproteins in type 2 diabetes," Educ. Res. Univ. Sci., vol. 3, no. 4, pp. 711-718, 2024.
45. M. A. Karimi, et al., "Lipid variability and risk of microvascular complications in patients with diabetes: a systematic review and meta-analysis," BMC Endocr. Disord., vol. 24, no. 1, p. 4, 2024.
46. S. Kandasamy, et al., "Serum neuron-specific enolase as a biomarker in diagnosing diabetic peripheral neuropathy: A cross-sectional study," 2022, vol. 13, no. 12.
47. J. Xie, et al., "The relationship between neuron-specific enolase, high sensitivity C reactive protein, and diabetic peripheral neuropathy in Chinese patients with type 2 diabetes: a prospective nested case–control analysis," Diabetes Res. Clin. Pract., vol. 44, no. 1, pp. 190-199, 2024.
48. F. Majeed, et al., "Potential predictive biomarker for diabetic peripheral neuropathy: serum neuron-specific enolase," Curr. Issues Pharm. Med. Sci., 2023.
49. Z. J. Ghaib, K. K. Ghudhaib, and F. Y. Mohsen, "Assessment of Neuron-Specific Enolase Level and some Related Biochemical Factors in Patients with Diabetic Peripheral Nerve Disorders," Indian J. Forensic Med. Toxicol., vol. 15, no. 3, 2021.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Fahad Ahmed
Department of Biochemistry, Sohail University, Karachi Pakistan /Institute of nursing & midwifery,Jinnah Sindh Medical University,Karachi,Pakistan
Shaista Emad
Department of Biochemistry, Jinnah Medical & Dental college/ Sohail University,Karachi, Pakistan
Rizwana Sanaullah Waraich
Biomedical Research Center, Department of Biomedical & Biological Sciences, Sohail University Karachi, Pakistan
Rubina Ghani
Department of Biochemistry, Jinnah Medical & Dental college/ Sohail University,Karachi, Pakistan
Khadija Shah
Indus College of Medical & Allied Health (IUHS /The Indus hospital),Karachi,Pakistan
Nazish Nizar Ali
Indus College of Medical & Allied Health (IUHS /The Indus hospital),Karachi,Pakistan
Shakila Qazi
Al-Hamra Medical Centre, Karachi Pakistan
Samina Jibran
Indus College of Medical & Allied Health (IUHS /The Indus hospital),Karachi,Pakistan
Atiya Rahman Rohilla
Indus College of Medical & Allied Health (IUHS /The Indus hospital),Karachi,Pakistan